课题基金 / 基金详情

Platform of synthetic specific promoters for immunotherapies and regenerative medicine

Platform of synthetic specific promoters for immunotherapies and regenerative medicine
用于免疫疗法和再生医学的合成特异性启动子平台
批准号：
455816
负责人：
Haddad Elie
金额：
$7.29万
依托单位：
Centre hospitalier universitaire Sainte-Justine (Montral, Qubec)
依托单位国家：
加拿大
项目类别：
Operating Grants
财政年份：
2021
资助国家：
加拿大
项目状态：
已结题
起止时间：
2021-09-01 至 2022-09-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=455816&lang=en
关键词：
Cancer Immunotherapy Car-Nk Cells Car-T Cells Chimeric Antigen Receptor Engineered Stem Cells Inducible Pluripotent Stem Cells Regenerative Medicine Solid Tumors Synthetic Specific Promoters Translational Aspect Of Gene Therapy

项目摘要

项目成果

Haddad Elie的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Targeted expression of a gene exclusively in a given cell type or tissue is not currently available. To address this gap, we have developed a technological platform that allows to design specific promoters, that target and limit gene expression to a speci
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
The interplay between Inborn Error of Immunity and blood disorders: unravelling immune defects behind common haematological diseases
Empowering innovative hematopoietic stem cells (HSC)-based cancer immunotherapy through the creation of synthetic specific promoters
New Modalities of Chimeric Antigen Receptor (CAR) Therapies in Pediatric Rhabdomyosarcoma
Alternatives to current Chimeric-Antigen Receptor (CAR)-T cell therapy in acute lymphoblastic leukemia
海外基金